



University of Kentucky
UKnowledge

Epidemiology Faculty Publications

Epidemiology

1-25-2016

Association of DNA Methylation at *CPT1A* Locus with Metabolic Syndrome in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study

Mithun Das

University of Alabama at Birmingham

Jin Sha

University of Alabama at Birmingham

Bertha Hidalgo

University of Alabama at Birmingham


Stella Aslibekyan

University of Alabama at Birmingham

Anh N. Do

University of Alabama at Birmingham

Follow this and additional works at: https://uknowledge.uky.edu/epidemiology_facpub

 Part of the [Biochemical Phenomena, Metabolism, and Nutrition Commons](#), and the [Epidemiology Commons](#).
Right click to open a feedback form in a new tab to let us know how this document benefits you.

Repository Citation

Das, Mithun; Sha, Jin; Hidalgo, Bertha; Aslibekyan, Stella; Do, Anh N.; Zhi, Degui; Sun, Dianjianyi; Zhang, Tao; Li, Shengxu; Chen, Wei; Srinivasan, Sathanur R.; Tiwari, Hemant K.; Absher, Devin; Ordovas, Jose M.; Berenson, Gerald S.; Arnett, Donna K.; and Irvin, Marguerite R., "Association of DNA Methylation at *CPT1A* Locus with Metabolic Syndrome in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study" (2016). *Epidemiology Faculty Publications*. 17.
https://uknowledge.uky.edu/epidemiology_facpub/17

This Article is brought to you for free and open access by the Epidemiology at UKnowledge. It has been accepted for inclusion in Epidemiology Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

Authors

Mithun Das, Jin Sha, Bertha Hidalgo, Stella Aslibekyan, Anh N. Do, Degui Zhi, Dianjianyi Sun, Tao Zhang, Shengxu Li, Wei Chen, Sathanur R. Srinivasan, Hemant K. Tiwari, Devin Absher, Jose M. Ordovas, Gerald S. Berenson, Donna K. Arnett, and Marguerite R. Irvin

Association of DNA Methylation at *CPT1A* Locus with Metabolic Syndrome in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study**Notes/Citation Information**

Published in *PLOS ONE*, v. 11, no. 1, e0145789, p. 1-9.

© 2016 Das et al.

This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Digital Object Identifier (DOI)

<https://doi.org/10.1371/journal.pone.0145789>

RESEARCH ARTICLE

Association of DNA Methylation at *CPT1A* Locus with Metabolic Syndrome in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study

Mithun Das¹, Jin Sha¹, Bertha Hidalgo¹, Stella Aslibekyan¹, Anh N. Do¹, Degui Zhi², Dianjianyi Sun³, Tao Zhang³, Shengxu Li³, Wei Chen³, Sathanur R. Srinivasan³, Hemant K. Tiwari², Devin Absher⁴, Jose M. Ordovas^{5,6}, Gerald S. Berenson³, Donna K. Arnett⁷, Marguerite R. Irvin^{1*}

1 Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, United States of America, **2** Department of Biostatistics, Section on Statistical Genetics, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, United States of America, **3** Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, United States of America, **4** HudsonAlpha Institute for Biotechnology, Huntsville, AL, United States of America, **5** Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, United States of America, **6** IMDEA Food, Madrid, Spain, **7** Dean's Office, College of Public Health, University of Kentucky, Lexington, KY, United States of America

* irvinr@uab.edu



OPEN ACCESS

Citation: Das M, Sha J, Hidalgo B, Aslibekyan S, Do AN, Zhi D, et al. (2016) Association of DNA Methylation at *CPT1A* Locus with Metabolic Syndrome in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study. PLoS ONE 11(1): e0145789. doi:10.1371/journal.pone.0145789

Editor: Tom R. Gaunt, University of Bristol, UNITED KINGDOM

Received: August 26, 2015

Accepted: December 8, 2015

Published: January 25, 2016

Copyright: © 2016 Das et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Data are available from dbGaP (http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000741.v1.p1).

Funding: The GOLDN study (DKA) was funded by the US National Institutes of Health (NIH)/National Heart, Lung and Blood Institutes (<http://www.nhlbi.nih.gov>) grants R01HL104135 and U01HL72524. The Bogalusa Heart Study (GSB) was supported by grants R01AG016592 from the National Institute on Aging (<https://www.nia.nih.gov>) and R01ES021724 from National Institute of Environmental Health Science (<http://www.niehs.nih.gov>). No individuals

Abstract

In this study, we conducted an epigenome-wide association study of metabolic syndrome (MetS) among 846 participants of European descent in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN). DNA was isolated from CD4+ T cells and methylation at ~470,000 cytosine-phosphate-guanine dinucleotide (CpG) pairs was assayed using the Illumina Infinium HumanMethylation450 BeadChip. We modeled the percentage methylation at individual CpGs as a function of MetS using linear mixed models. A Bonferroni-corrected P-value of 1.1×10^{-7} was considered significant. Methylation at two CpG sites in *CPT1A* on chromosome 11 was significantly associated with MetS (P for cg00574958 = 2.6×10^{-14} and P for cg17058475 = 1.2×10^{-9}). Significant associations were replicated in both European and African ancestry participants of the Bogalusa Heart Study. Our findings suggest that methylation in *CPT1A* is a promising epigenetic marker for MetS risk which could become useful as a treatment target in the future.

Introduction

Metabolic syndrome (MetS) is a constellation of interrelated risk factors of metabolic origin [1]. Persons with MetS are at twice the risk for cardiovascular disease (CVD) and have a five-fold risk for type 2 diabetes (T2D) [2]. Both genetic and environmental factors play a role in the pathogenesis of MetS. Genetic studies of MetS have often shown that genetic predisposition

employed or contracted by the funders played any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist. Dr. Absher is affiliated with HudsonAlpha Institute for Biotechnology of Huntsville, Alabama, United States of America, a non-profit institute dedicated to research, education, and enterprise. This affiliation does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

is attributable to the individual traits rather than the syndrome as a whole and that MetS is a clinical rather than biological phenomenon [3, 4]. However, genome-wide association studies (GWAS) for the individual components of MetS have reported the same loci as being associated with more than one MetS-related trait. To date genetic association studies for MetS have reported modest associations [5].

Few studies have scanned the epigenome for MetS or its constituent risk factors. One study found that individuals with MetS have global DNA hypomethylation relative to those without the syndrome; however, those results were not replicated and that study did not consider methylation at individual loci [6]. Since the epigenome directly impacts gene expression and can be modified by both genetic and environmental factors, epigenetic modifications are prime for further study [7]. We present a DNA methylation epigenome-wide association study (EWAS) of MetS in subjects of European descent from the Genetics of Lipid Lowering Drugs and Diet Network Study (GOLDN). Our top results were validated in the Bogalusa Heart Study (BHS), an external study population comprising participants of both European and African ancestry.

Research Design and Methods

Discovery Study

The GOLDN study is composed of families of European descent recruited from field centers in Minneapolis, MN and Salt Lake City, UT. It is part of the NHLBI Family Heart Study and has been described in detail in prior publications [8–10]. Written consent was obtained from each participant during the screening visit; GOLDN included no participants under the age of full legal responsibility (i.e., < 18 yr). The GOLDN study protocol was approved by the Institutional Review Boards at the University of Minnesota, University of Utah, Tufts University/New England Medical Center, and the University of Alabama at Birmingham. We restricted our analysis to individuals aged 30 years and above since many of the risk factors that constitute MetS generally occur in middle age or later. For the present study, 846 individuals aged ≥ 30 years were selected out of 994 participants with available methylation data.

Height, weight, and waist circumference (WC) were measured, and body mass index (BMI) was calculated using standard methods [11]. Blood pressure (BP) was measured with an automated oscillometric device, with participants in a seated position after five minutes of rest. Triglycerides (TG), high density lipoprotein cholesterol (HDLc), and fasting blood glucose (FBG) were measured after ≥ 12 hours of fasting using the Roche/Hitachi 911 automated analyzer. MetS was defined using the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) guidelines [12].

DNA was isolated from CD4+ T cells harvested from frozen buffy coat samples with positive selection by antigen-specific magnetic beads. The Illumina Infinium HumanMethylation450 BeadChip (Illumina Inc, San Diego, CA) was used to quantify methylation at $\sim 470,000$ autosomal cytosine-phosphate-guanine dinucleotide pairs (CpGs) as described in previous publications [8–10, 13]. Principal components (PCs) were generated using the *prcomp* function in R (V 2.12.1) based on the methylation level of all autosomal CpGs that passed quality control. Similarly to previous publications in GOLDN, these PCs were used to adjust for T-cell purity in the association analysis [8–10].

Statistical Methods

Participant characteristics were compared between individuals with and without MetS by using t-tests. We used a linear mixed model to test for association between methylation at each CpG site and MetS, adjusting for age, sex, study site, and four methylation PCs as fixed effects, and family structure as a random effect using the R kinship package (*lmekin* function). A

Bonferroni correction was used to adjust for the number of CpGs tested, where alpha was set to $0.05/470000 = 1.1 \times 10^{-7}$. Our top CpG finding was tested for association with each individual component of MetS using similar linear mixed models. We also used a t-test to compare methylation levels at our top CpG site by MetS criteria for each component (WC ≥ 102 cm for men and ≥ 88 cm for women, HDLc < 40 mg/dL for men and < 50 mg/dL for women, TG ≥ 150 mg/dL, BP $\geq 130 / \geq 85$ mm Hg, and FBG ≥ 100 mg/dL).

Replication Population

The Bogalusa Heart Study (BHS), initiated in 1973 as an epidemiologic study of cardiovascular risk factors in children and adolescents, is ongoing [14]. No BHS participants used in this analysis were under the age of full legal responsibility (i.e., < 18 yr), and written consent was obtained from each participant. Study protocols were approved by the Institutional Review Board of the Tulane University Health Sciences Center. Anthropometry, BP, lipids, and glucose were measured after overnight fasting. DNA methylation profiles from whole blood were assessed in 872 individuals who were ≥ 29 years at the time of the methylation assays (603 with European ancestry and 269 with African ancestry). The BHS used the Infinium Human-Methylation450 BeadChip, similarly to GOLDN. To test the association between DNA methylation at CpG sites as the outcome and MetS as a predictor, a linear mixed model was fitted using the R package CpGassoc [15] separately for African Americans and European Americans. Covariates included in the models were age, gender, and white blood cell differential count proportions as fixed effects, and batch as a random effect. The top two CpGs from the GOLDN discovery study were tested for replication in BHS. Therefore, the Bonferroni correction for replication was set at $0.05/2 = 2.50 \times 10^{-2}$.

The results of the GOLDN and BHS were meta-analyzed by Fisher's Z score method [16] to obtain the cumulative distribution function of the P-value.

Results

Characteristics of the GOLDN population ($n = 846$) with and without MetS are presented in Table 1. The mean age of participants was 53.3 years; 48.5% were female, and 52.7% were recruited from the Minnesota site. By definition participants with MetS in GOLDN ($N = 365$) had significantly higher BMI, WC, TG, FBG, systolic (SBP) and diastolic (DBP) blood pressure ($P < 0.0001$), and significantly lower HDLc ($P < 0.0001$).

The Manhattan plot in Fig 1 shows association results from the GOLDN analysis. Two statistically significant CpGs in the carnitine palmitoyltransferase 1 A gene (*CPT1A*) from the EWAS of MetS in GOLDN are presented in Table 2. Results show lower methylation at cg00574958 ($P = 2.6 \times 10^{-14}$) and cg17058475 ($P = 1.2 \times 10^{-9}$) is associated with the presence of MetS. The CpGs are located only ~ 100 base pairs apart, and methylation at each site is significantly correlated ($r = 0.85$, $P < 2.2 \times 10^{-16}$). Fig 2 illustrates the average difference in DNA methylation level (%) with respect to MetS status for each of the five traits that define it. We observed lower methylation at cg00574958 was significantly associated with meeting WC, TG, BP, and FBG criteria for MetS with $P < 0.001$ and the HDLc criterion with $P < 0.01$. Upon parallel analyses, results for cg17058475 had the same direction of effect and similar significance for each MetS criteria with the exception that the association result for blood pressure was more marginal, with $P < 0.05$.

Characteristics of the BHS European-American and African-American populations are also presented in Table 1. BHS participants are comparable to the GOLDN population except they are, on average, younger ($P < 0.0001$). The results of the replication analysis for the 2 CpGs in *CPT1A* in the BHS are given in Table 2. Both CpGs were significantly associated with MetS

Table 1. Descriptive statistics (mean ± standard deviation) of GOLDN and Bogalusa Heart Study participants with and without MetS.

| | GOLDN | | Bogalusa Heart Study | | | |
|--------------------------|-------------|-------------------------|----------------------|-------------------------|--------------------|-------------------------|
| | MetS+ | MetS- | MetS+* | MetS-* | MetS+ [§] | MetS- [§] |
| N | 365 | 481 | 249 | 354 | 117 | 152 |
| Age (years) | 57.7±12.6 | 49.9±12.8 [†] | 44.1±4.1 | 43.1±4.6** | 43.5±4.5 | 43.1±4.5 |
| Weight (kg) | 93.4±16.1 | 77.3±15.9 [†] | 100.5±21.7 | 77.9±17.3 [¶] | 107.0±24.2 | 80.8±20.9 [¶] |
| BMI (kg/m ²) | 32.0±5.1 | 26.4±4.4 [†] | 34.3±7.0 | 27.3±5.3 [¶] | 37.3±7.8 | 28.7±7.5 [¶] |
| WC (cm) | 107.8±12.6 | 91.0±13.6 [†] | 109.4±15.4 | 91.3±12.7 [¶] | 111.4±15.0 | 93.3±15.7 [¶] |
| TG (mg/dl) | 199.8±114.1 | 102.5±54.0 [†] | 194.5±112.6 | 106.3±55.3 [¶] | 143.9±105.2 | 95.5±67.6 [¶] |
| HDLc (mg/dl) | 40.6±10.7 | 52.3±13.1 [†] | 39.0±10.1 | 50.0±14.2 [¶] | 41.3±10.9 | 55.6±15.9 [¶] |
| FBG (mg/dl) | 110.3±19.4 | 96.4±11.4 [†] | 105.0±32.6 | 87.6±16.0 [¶] | 113.8±50.4 | 91.6±31.2 [¶] |
| SBP (mmHg) | 124.4±17.8 | 112.5±15.4 [†] | 120.1±11.8 | 111.5±10.7 [¶] | 133.8±20.5 | 121.0±17.1 [¶] |
| DBP (mmHg) | 71.6±10.4 | 68.1±8.9 [†] | 78.2±7.9 | 71.8±7.2 [¶] | 84.7±12.3 | 75.7±10.4 [¶] |

Data are presented as means ± SD. BMI, body mass index; DBP, diastolic blood pressure; FBG, fasting blood glucose; GOLDN, Genetics of Lipid Lowering Drugs and Diet Network Study; HDLc, high density lipoprotein cholesterol; MetS-, participants without metabolic syndrome; MetS+, participants with metabolic syndrome; SBP, systolic blood pressure; TG, triglycerides; WC, waist circumference.

* Bogalusa Heart Study European Americans;

§ Bogalusa Heart Study African Americans;

† P ≤ 0.0001 for MetS+ vs. MetS- comparison;

¶ 0.0001 < P ≤ 0.001 for MetS+ vs. MetS- comparison;

** 0.001 < P ≤ 0.01 for MetS+ vs. MetS- comparison.

doi:10.1371/journal.pone.0145789.t001

among both European Americans and African Americans. The meta-analysis of all three populations (GOLDN, Bogalusa European Americans and Bogalusa African Americans) demonstrated highly significant P-values for both CpGs—cg00574958 (2.6×10^{-23}) and cg17058475 (1.4×10^{-13}). Similarly, the meta-analysis of GOLDN and Bogalusa European Americans also demonstrated significant P-values for both cg00574958 (6.7×10^{-22}) and cg17058475 (2.06×10^{-12}).

Discussion

Our study is the first to report an association between MetS and CPT1A DNA methylation. We observed an inverse relationship between methylation at two loci (cg00574958 and




Fig 1. Epigenome-wide association Manhattan plot for MetS in the GOLDN dataset (n = 846). MetS; metabolic syndrome. The blue line indicates a marginal significance level of 1.0×10^{-5} ; the red line indicates the genome-wide significance level of 1.1×10^{-7} .

doi:10.1371/journal.pone.0145789.g001

Table 2. Association of top two CpGs for MetS in GOLDN discovery and replication in BHS.

| CpG | Chromosome | Gene | Location | β (SE) | P |
|-----------------------------|------------|--------------|----------|---------------------------------|------------------------|
| <i>GOLDN (N = 846)</i> | | | | | |
| cg00574958 | 11 | <i>CPT1A</i> | 68607622 | -0.026 (3.38x10 ⁻³) | 2.55x10 ⁻¹⁴ |
| cg17058475 | 11 | <i>CPT1A</i> | 68607737 | -0.027 (4.3x10 ⁻³) | 1.21x10 ⁻⁹ |
| <i>BHS Whites (N = 603)</i> | | | | | |
| cg00574958 | 11 | <i>CPT1A</i> | 68607622 | -0.009 (1.50x10 ⁻³) | 3.96x10 ⁻⁹ |
| cg17058475 | 11 | <i>CPT1A</i> | 68607737 | -0.007 (1.89x10 ⁻³) | 2.18x10 ⁻⁴ |
| <i>BHS Blacks (N = 269)</i> | | | | | |
| cg00574958 | 11 | <i>CPT1A</i> | 68607622 | -0.007 (2.64x10 ⁻³) | 4.90x10 ⁻³ |
| cg17058475 | 11 | <i>CPT1A</i> | 68607737 | -0.007 (3.30x10 ⁻³) | 1.74x10 ⁻² |

BHS, Bogalusa Heart Study; CpG, cytosine-phosphate-guanine dinucleotide; GOLDN, Genetics of Lipid Lowering Drugs and Diet Network Study.

doi:10.1371/journal.pone.0145789.t002

cg17058475) in *CPT1A* and MetS overall as well as with specific MetS components. The findings were successfully replicated in BHS participants of European and African Ancestry. The meta-analyses showed highly significant associations of these CpGs with MetS. On balance, our findings indicate that decreased methylation at two intronic loci of *CPT1A* is associated with increased metabolic risk and overall MetS.

Other studies in GOLDN have highlighted this methylation locus for lipids. Specifically, we reported inverse associations between methylation at cg00574958 and cg17058475 and total number and concentration of small LDL particles, large and medium VLDL particles, and LDL




Fig 2. Differences in mean DNA methylation (%) of cg00574958 in *CPT1A* by risk factors of MetS. X-axis shows the criteria met (yes/no) for each component of MetS; Y-axis the mean DNA methylation (%) with error bars showing standard error. *P < 0.01, **P < 0.001. Black bars, MetS criteria not met; gray bars, MetS criteria met. MetS criteria include the following: waist circumference \geq 102 cm for men and \geq 88 cm for women; high-density lipoprotein cholesterol < 40 mg/dL for men and < 50 mg/dL for women; triglycerides \geq 150 mg/dL; blood pressure (systolic/diastolic) \geq 130 / \geq 85 mm Hg; and fasting blood glucose \geq 100 mg/dL.

doi:10.1371/journal.pone.0145789.g002

diameter [8]. Methylation at the same loci, along with two nearby CpGs, was also found to be inversely related to fasting TG and very low density lipoprotein cholesterol (VLDLc) in a separate analysis, results which successfully replicated in the Framingham Heart Study (FHS) [10]. That report also demonstrated that nearby SNPs from GWAS (located within 1 Mb up or down stream of this locus, representing 1369 SNPs) did not influence these CpGs of interest, and that increased methylation at cg00574958 was associated with decreased *CPT1A* expression [10, 17]. The most significant CpG site (cg00574958) was validated by bisulfite resequencing [10]. Since high TG (≥ 110 mg/dL) is a component of MetS, we tested the association between the other components of MetS (SBP, DBP, FBG, WC, and HDLc as quantitative traits) and cg00574958 while adjusting for TG. Upon adjustment for fasting TG, cg00574958 was associated with WC ($P = 7.2 \times 10^{-6}$), HDLc ($P = 3.8 \times 10^{-2}$), and FBG ($P = 7.6 \times 10^{-3}$) but not with SBP ($P = 0.11$) or DBP ($P = 0.18$). These persistent results suggest that *CPT1A* methylation has pleiotropic effects across multiple components of MetS, and the results of this study do not only reflect the gene's previously demonstrated association with TG.

CPT1A is one of the three isoforms of CPT-1, mostly found in the liver (also known as L-CPT-1). CPT-1 is an important enzyme involved in the regulation of mitochondrial fatty acid oxidation (FAO). It catalyzes the conversion of cytoplasmic long-chain acyl CoA to acyl-carnitine (i.e., connecting long-chain fatty acids to carnitine), which then enters into the mitochondria for fatty acid β -oxidation [18]. *CPT1A* deficiency is a rare metabolic disorder of FAO caused by functional mutations in the gene [19]. GWAS studies have also linked the gene to fatty acid metabolism but not clinical metabolic phenotypes [20, 21]. Several points of evidence suggest that CPT-1 may be a promising target for the development of therapeutic agents against diabetes and obesity; however, a better understanding of metabolic changes following *CPT1A* manipulation is needed [22]. In particular, a decrease in mitochondrial fatty acid uptake results in elevated intramuscular lipid levels which are associated with insulin resistance. However, CPT-1 inhibition has been linked to reduced FAO, but upregulated glucose oxidation and improved whole-body glucose tolerance and insulin sensitivity in a mouse model [18, 23]. Further supporting the potential clinical relevance of our findings, studies of carnitine supplementation have reported improved FAO, reduced oxidative stress, as well as improved lipid metabolism [24–26]. Overall, our study contributes to the growing body of evidence in support of pursuing therapeutics centered on the CPT enzymes and/or their biochemical pathways.

The two CpGs highlighted are located in intron 1 which is an active regulatory region according to ENCODE [27]. This region is a 4 kb promoter-associated region surrounding the transcription start site (TSS) of *CPT1A* in the HepG2 cell line ("Active TSS" according to chromHMM) [28]. There are several transcription factor binding sites near our highlighted CpGs. More than one of the annotated transcription factors is involved in lipid metabolism, including sterol regulatory element-binding proteins (SREBPs), peroxisome proliferator-activated receptor gamma (PPAR- γ), and upstream transcription factor 1 (USF1) [29–31]. The two CpGs are between two CpG islands. Given this functional evidence and observed associations between methylation and gene expression in the previous GOLDN study, we speculate the methylation state of these two CpG sites in intron 1 may be indicative of the promoter activity of *CPT1A*.

Our study has several strengths and a few limitations of note. Among the advantages of our data are the epigenome-wide coverage of methylation variation and successful replication in more than one racial group. Our study is, however, limited by the cross-sectional nature of GOLDN and BHS as well as the focus on DNA derived only from blood cell types. In particular, we observed an inverse association between MetS and methylation at two CpG sites in *CPT1A* (i.e. having MetS is associated with lower methylation). Given that *CPT1A* promotes

fatty acid metabolism (improving lipid levels and glucose) and that prior research in GOLDN and FHS has linked increased methylation at cg00574958 with decreased gene expression, we expected MetS to correlate with higher methylation at that site. Given our findings, we considered that the metabolic environment of MetS may change methylation at this site in favor of gene expression. Additionally, we considered that the relationship between this locus and MetS could differ by tissue type. Notably, data from the Multiple Tissue Human Expression Resource (MuTHER) Cohort shows cg00574958 is positively associated with TG in adipose tissue [32]. Moreover both cg00574958 and cg17058475 are lowly methylated in three of the five cell lines from ENCODE (GM12878/lymphoblastoid cell line, H1-hESC/embryonic stem cells, K562/leukemia cell line), but partially methylated in the HELA-S3/cervical carcinoma and HepG2/hepatocellular carcinoma cell line [27]. Future research is greatly needed to continue to unravel the relationship between CPT1A and MetS as well as its individual components, especially given the potential therapeutic relevance of this finding.

In conclusion, we identified an inverse association between methylation at intronic loci of *CPT1A* and MetS as well as individual MetS components. The significant findings observed in GOLDN replicated in both European-American and African-American populations of BHS, strengthening the validity of our observations and showing similarity across different racial groups. In light of other GOLDN studies highlighting this locus, we confirmed these findings as distinct, suggesting pleiotropic effects. Our study generates the hypothesis that methylation at the two *CPT1A* loci may play a role in an ultimate predisposition towards MetS. Future research could help to determine whether this locus can be treated as a target region for personalized prevention and treatment of metabolic disorders, including MetS and T2D.

Author Contributions

Conceived and designed the experiments: DKA JMO DA WC GSB. Performed the experiments: DKA JMO WC GSB. Analyzed the data: MD MRI HKT DZ JS DS TZ SL. Wrote the paper: MD BH SA AND DZ HKT JMO DKA MRI DS TZ SL WC GSB SRS.

References

1. Grundy SM. A constellation of complications: the metabolic syndrome. *Clinical cornerstone*. 2005; 7(2–3):36–45. PMID: [16473259](#)
2. Grundy SM, Adams-Huet B, Vega GL. Variable contributions of fat content and distribution to metabolic syndrome risk factors. *Metabolic syndrome and related disorders*. 2008; 6(4):281–8. Epub 2008/09/02. doi: [10.1089/met.2008.0026](#) PMID: [18759660](#)
3. Kristiansson K, Perola M, Tikkanen E, Kettunen J, Surakka I, Havulinna AS, et al. Genome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits. *Circ Cardiovasc Genet*. 2012; 5(2):242–9. doi: [10.1161/CIRCGENETICS.111.961482](#) PMID: [22399527](#)
4. Kams R, Succop P, Zhang G, Sun G, Indugula SR, Havas-Augustin D, et al. Modeling metabolic syndrome through structural equations of metabolic traits, comorbid diseases, and GWAS variants. *Obesity (Silver Spring)*. 2013; 21(12):E745–54.
5. Kraja AT, Chasman DI, North KE, Reiner AP, Yanek LR, Kilpelainen TO, et al. Pleiotropic genes for metabolic syndrome and inflammation. *Mol Genet Metab*. 2014; 112(4):317–38. doi: [10.1016/j.ymgme.2014.04.007](#) PMID: [24981077](#)
6. Luttmer R, Spijkerman AM, Kok RM, Jakobs C, Blom HJ, Serne EH, et al. Metabolic syndrome components are associated with DNA hypomethylation. *Obesity research & clinical practice*. 2013; 7(2):e106–e15.
7. Ling C, Groop L. Epigenetics: a molecular link between environmental factors and type 2 diabetes. *Diabetes*. 2009; 58(12):2718–25. Epub 2009/11/27. doi: [10.2337/db09-1003](#) PMID: [19940235](#)
8. Frazier-Wood AC, Aslibekyan S, Absher DM, Hopkins PN, Sha J, Tsai MY, et al. Methylation at CPT1A locus is associated with lipoprotein subfraction profiles. *J Lipid Res*. 2014; 55(7):1324–30. PMID: [24711635](#)

9. Hidalgo B, Irvin MR, Sha J, Zhi D, Aslibekyan S, Absher D, et al. Epigenome-Wide Association Study of Fasting Measures of Glucose, Insulin, and HOMA-IR in the Genetics of Lipid Lowering Drugs and Diet Network Study. *Diabetes*. 2014; 63(2):801–7. doi: [10.2337/db13-1100](https://doi.org/10.2337/db13-1100) PMID: [24170695](https://pubmed.ncbi.nlm.nih.gov/24170695/)
10. Irvin MR, Zhi D, Joehanes R, Mendelson M, Aslibekyan S, Claas SA, et al. Epigenome-wide association study of fasting blood lipids in the Genetics of Lipid-lowering Drugs and Diet Network study. *Circulation*. 2014; 130(7):565–72. doi: [10.1161/CIRCULATIONAHA.114.009158](https://doi.org/10.1161/CIRCULATIONAHA.114.009158) PMID: [24920721](https://pubmed.ncbi.nlm.nih.gov/24920721/)
11. Warodomwicit D, Shen J, Arnett DK, Tsai MY, Kabagambe EK, Peacock JM, et al. ADIPOQ polymorphisms, monounsaturated fatty acids, and obesity risk: the GOLDN study. *Obesity (Silver Spring)*. 2009; 17(3):510–7.
12. Grundy SM, Brewer HB Jr., Cleeman JI, Smith SC Jr., Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. *Circulation*. 2004; 109(3):433–8. PMID: [14744958](https://pubmed.ncbi.nlm.nih.gov/14744958/)
13. Absher DM, Li X, Waite LL, Gibson A, Roberts K, Edberg J, et al. Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations. *PLoS Genet*. 2013; 9(8):e1003678. doi: [10.1371/journal.pgen.1003678](https://doi.org/10.1371/journal.pgen.1003678) PMID: [23950730](https://pubmed.ncbi.nlm.nih.gov/23950730/)
14. Berenson GS. Bogalusa Heart Study: a long-term community study of a rural biracial (Black/White) population. *Am J Med Sci*. 2001; 322(5):293–300. PMID: [11876192](https://pubmed.ncbi.nlm.nih.gov/11876192/)
15. Barfield RT, Kilaru V, Smith AK, Conneely KN. CpGassoc: an R function for analysis of DNA methylation microarray data. *Bioinformatics*. 2012; 28(9):1280–1. doi: [10.1093/bioinformatics/bts124](https://doi.org/10.1093/bioinformatics/bts124) PMID: [22451269](https://pubmed.ncbi.nlm.nih.gov/22451269/)
16. Evangelou E, Ioannidis JP. Meta-analysis methods for genome-wide association studies and beyond. *Nat Rev Genet*. 2013; 14(6):379–89. doi: [10.1038/nrg3472](https://doi.org/10.1038/nrg3472) PMID: [23657481](https://pubmed.ncbi.nlm.nih.gov/23657481/)
17. Zhi D, Aslibekyan S, Irvin MR, Claas SA, Borecki IB, Ordovas JM, et al. SNPs located at CpG sites modulate genome-epigenome interaction. *Epigenetics*. 2013; 8(8):802–6. doi: [10.4161/epi.25501](https://doi.org/10.4161/epi.25501) PMID: [23811543](https://pubmed.ncbi.nlm.nih.gov/23811543/)
18. Keung W, Ussher JR, Jaswal JS, Raubenheimer M, Lam VH, Wagg CS, et al. Inhibition of carnitine palmitoyltransferase-1 activity alleviates insulin resistance in diet-induced obese mice. *Diabetes*. 2013; 62(3):711–20. doi: [10.2337/db12-0259](https://doi.org/10.2337/db12-0259) PMID: [23139350](https://pubmed.ncbi.nlm.nih.gov/23139350/)
19. Bonnefont JP, Demaugre F, Prip-Buus C, Saudubray JM, Brivet M, Abadi N, et al. Carnitine palmitoyltransferase deficiencies. *Mol Genet Metab*. 1999; 68(4):424–40. PMID: [10607472](https://pubmed.ncbi.nlm.nih.gov/10607472/)
20. Kettunen J, Tukiainen T, Sarin AP, Ortega-Alonso A, Tikkanen E, Lyytikäinen LP, et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. *Nat Genet*. 2012; 44(3):269–76. doi: [10.1038/ng.1073](https://doi.org/10.1038/ng.1073) PMID: [22286219](https://pubmed.ncbi.nlm.nih.gov/22286219/)
21. Comuzzie AG, Cole SA, Laston SL, Voruganti VS, Haack K, Gibbs RA, et al. Novel genetic loci identified for the pathophysiology of childhood obesity in the Hispanic population. *PLoS One*. 2012; 7(12):e51954. doi: [10.1371/journal.pone.0051954](https://doi.org/10.1371/journal.pone.0051954) PMID: [23251661](https://pubmed.ncbi.nlm.nih.gov/23251661/)
22. Jogl G, Hsiao YS, Tong L. Structure and function of carnitine acyltransferases. *Ann N Y Acad Sci*. 2004; 1033:17–29. PMID: [15591000](https://pubmed.ncbi.nlm.nih.gov/15591000/)
23. Schooneman MG, Vaz FM, Houten SM, Soeters MR. Acylcarnitines: reflecting or inflicting insulin resistance? *Diabetes*. 2013; 62(1):1–8. doi: [10.2337/db12-0466](https://doi.org/10.2337/db12-0466) PMID: [23258903](https://pubmed.ncbi.nlm.nih.gov/23258903/)
24. Cahova M, Chrastina P, Hansikova H, Drahota Z, Trnovska J, Skop V, et al. Carnitine supplementation alleviates lipid metabolism derangements and protects against oxidative stress in non-obese hereditary hypertriglyceridemic rats. *Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme*. 2015; 40(3):280–91. doi: [10.1139/apnm-2014-0163](https://doi.org/10.1139/apnm-2014-0163) PMID: [25723909](https://pubmed.ncbi.nlm.nih.gov/25723909/)
25. Malaguamera M, Vacante M, Avitabile T, Malaguamera M, Cammalleri L, Motta M. L-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes. *Am J Clin Nutr*. 2009; 89(1):71–6. doi: [10.3945/ajcn.2008.26251](https://doi.org/10.3945/ajcn.2008.26251) PMID: [19056606](https://pubmed.ncbi.nlm.nih.gov/19056606/)
26. Derosa G, Cicero AF, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. *Clin Ther*. 2003; 25(5):1429–39. PMID: [12867219](https://pubmed.ncbi.nlm.nih.gov/12867219/)
27. Siggens L, Ekwall K. Epigenetics, chromatin and genome organization: recent advances from the ENCODE project. *J Intern Med*. 2014; 276(3):201–14. doi: [10.1111/joim.12231](https://doi.org/10.1111/joim.12231) PMID: [24605849](https://pubmed.ncbi.nlm.nih.gov/24605849/)
28. Ernst J, Kellis M. ChromHMM: automating chromatin-state discovery and characterization. *Nat Methods*. 2012; 9(3):215–6. doi: [10.1038/nmeth.1906](https://doi.org/10.1038/nmeth.1906) PMID: [22373907](https://pubmed.ncbi.nlm.nih.gov/22373907/)
29. Lee JC, Lusis AJ, Pajukanta P. Familial combined hyperlipidemia: upstream transcription factor 1 and beyond. *Curr Opin Lipidol*. 2006; 17(2):101–9. PMID: [16531745](https://pubmed.ncbi.nlm.nih.gov/16531745/)
30. Eberle D, Hegarty B, Bossard P, Ferre P, Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. *Biochimie*. 2004; 86(11):839–48. PMID: [15589694](https://pubmed.ncbi.nlm.nih.gov/15589694/)

31. Huang JV, Greyson CR, Schwartz GG. PPAR- γ as a therapeutic target in cardiovascular disease: evidence and uncertainty. *J Lipid Res.* 2012; 53(9):1738–54. doi: [10.1194/jlr.R024505](https://doi.org/10.1194/jlr.R024505) PMID: [22685322](https://pubmed.ncbi.nlm.nih.gov/22685322/)
32. Pfeiffer L, Wahl S, Pilling LC, Reischl E, Sandling JK, Kunze S, et al. DNA methylation of lipid-related genes affects blood lipid levels. *Circ Cardiovasc Genet.* 2015; 8(2):334–42. doi: [10.1161/CIRCGENETICS.114.000804](https://doi.org/10.1161/CIRCGENETICS.114.000804) PMID: [25583993](https://pubmed.ncbi.nlm.nih.gov/25583993/)